A review examined alkaloids from Fritillariae Cirrhosae Bulbus to see how they might affect various health issues. The study looked at conditions including respiratory diseases, tumors, and hypertension. It also checked for effects like expectorant, antitussive, dispersing swelling, anti-tumor, antihypertensive, antioxidant, antiasthmatic, and antibacterial properties. No specific safety concerns were reported in this review. The study did not report on adverse events, serious adverse events, discontinuations, or tolerability. Because the active metabolites were unclear and their mechanisms of action were not fully explained, the findings remain uncertain. This review offers a reference for further research and clinical application. Readers should understand that this is a review and not a new trial. The evidence is limited and does not yet prove these substances work for people. More studies are needed to confirm these effects and ensure safety before they are widely used in practice.
Alkaloids from Fritillariae Cirrhosae Bulbus show promise for multiple health conditions
Photo by Div / Unsplash
What this means for you:
This review suggests potential benefits but notes unclear mechanisms and a need for more research. More on Hypertension
Systematic review synthesizes Rhaponticum species chemistry, traditional uses, and research gaps across multiple conditions Ancient Herbs May Help Modern Health
Frontiers · Apr 24, 2026
Network meta-analysis shows exercise modalities reduce blood pressure in adults with prehypertension or hypertension Combined training and high-intensity interval training lower blood pressure in adults with prehypertension and hypertension
· May 19, 2026
Narrative review on tumor antigen-associated autoantibodies in cancer diagnosis and treatment Tumor antibodies show a complex dual role in cancer growth and defense
Frontiers · May 18, 2026
Case report and review of literature on acute NSTEMI after fluorescein angiography in a 76-year-old woman Rare heart attack possible after fluorescein angiography in older adults with heart disease
Frontiers · May 18, 2026